Technology Research and Development Project 2 (BCI2000-Based Laboratory and Clinical Systems)

自适应神经技术的开发和使用本身就是一项多学科的努力，涉及 神经科学、生物医学工程、电气和计算机科学以及临床领域。为了促进这些 Endeavors，BCI2000，一个软件平台，它实现了与 CNS是在过去20年中开发和传播的；它支持广泛的自适应 神经科技。到目前为止，BCI2000已在全球范围内提供给6000多名用户；他们已经将其用于 在1200多个同行评议的出版物中描述的实时实验。新的NIH支持确保BCI2000的S 继续开发、验证和传播，从而确保其继续增强 它的用户的科学fic生产力。 在这个幸运的新环境中，BCI2000的持续生存得到了保证，使tr&d2能够专注于 它努力提供基于BCI2000的新型系统，以满足主要类别的自适应神经技术 研究和开发。T&D2的S下一个授权期的目标是生产两个适应性很强的系统 支持重要的实验室或临床研究。这些系统将与以下机构合作开发 Tr&d1和tr&d3，它们最初将服务于这些tr&d和tr&d3的目标以及所有三个项目的协作项目 R&D。Tr&d2有两个特定的fic目标： 目标1.为小型实验动物开发一种完全植入的遥测系统，支持长期 与中枢神经系统24/7相互作用，并可针对特定的fic中枢神经系统通路的可塑性。这一新系统将是 与三角生物系统公司合作开发、优化和验证。并与R&D 1合作， 这将植入它并在老鼠身上使用。该系统将使执行、传播和探索 各种各样的靶向可塑性方案，包括那些使用操作性条件反射、配对刺激或 其他养生法。 目标2.开发一种能够对皮质网络进行功能分析并支持干预的临床系统 这可以针对这些网络和他们所贡献的行为的有益变化。在合作中 与tr&d3合作并与古格技术公司密切合作，tr&d2将开发一种可以绘制地图的床边系统 通过脑电地形图(ECoG)和/或立体脑图刺激和记录这些网络 (SEEG)电极阵列，并可以通过使用闭环反馈和其他方法来靶向其中的Modifi阳离子。 这一新的临床研究系统将鼓励制定指导可塑性的方案的研究，以恢复 因创伤或疾病而受损的认知或感觉运动行为。 通过创建、验证和传播这些系统，tr&d2将为科学家、工程师和临床医生提供 具有解决重要科学fic和临床问题的新能力。这些新颖的系统将推动 开发和使用新的神经技术，以减少神经疾病的破坏性影响。

The development and use of adaptive neurotechnologies is an inherently multidisciplinary endeavor, involving neuroscience, biomedical engineering, electrical and computer science, and clinical domains. To facilitate these endeavors, BCI2000, a software platform that implements complex real-time closed-loop interactions with the CNS, has been developed and disseminated over the past 20 years; it supports a wide range of adaptive neurotechnologies. To date, BCI2000 has been provided to more than 6,000 users worldwide; they have used it for real-time experiments described in over 1,200 peer-reviewed publications. New NIH support ensures BCI2000's continued development, validation, and dissemination, and thereby ensures its continued ability to enhance the scientific productivity of its users. This fortunate new environment, in which the continued viability of BCI2000 is assured, enables TR&D2 to focus its efforts on providing novel BCI2000-based systems that address major categories of adaptive neurotechnology research and development. TR&D2's goal for the next grant period is to produce two highly adaptable systems that support important laboratory or clinical investigations. These systems will be developed in cooperation with TR&D1 and TR&D3, and they will initially serve the aims of these TR&Ds and the collaborative projects of all three TR&Ds. TR&D2 has two specific aims: Aim 1. To develop a wholly implanted telemetry-based system for small laboratory animals that supports long-term 24/7 interactions with the CNS and can target plasticity to specific CNS pathways. This new system will be developed, optimized, and validated in collaboration with Triangle Biosystems, Intl. and in cooperation with TR&D1, which will implant it and use it in rats. The system will enable the implementation, dissemination and exploration of a wide variety of targeted-plasticity protocols, including those that use operant conditioning, paired stimulation, or other regimens. Aim 2. To develop a clinical system that enables functional analysis of cortical networks and supports interventions that can target beneficial changes in these networks and in the behaviors to which they contribute. In cooperation with TR&D3 and working closely with Guger Technologies, TR&D2 will develop a bedside system that can map these networks by stimulating and recording through electrocorticographic (ECoG) and/or stereoencephalographic (SEEG) electrode arrays and can target modifications in them by using closed-loop feedback and other methods. This new clinical research system will encourage studies that develop protocols to guide plasticity so as to restore cognitive or sensorimotor behaviors impaired by trauma or disease. By creating, validating, and disseminating these systems, TR&D2 will provide scientists, engineers, and clinicians with new ability to address important scientific and clinical problems. These novel systems will advance the development and use of new neurotechnologies that can reduce the devastating impact of neurological disorders.